Clinical Trials Browser

NCT07502300 2026-04-14

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

Phase 3 Not yet recruiting

562 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

Phase 3 Not yet recruiting

494 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07441681 2026-04-03

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Phase 3 Not yet recruiting

454 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07472517 2026-03-31

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Phase 3 Not yet recruiting

670 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Not yet recruiting

574 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07383116 2026-02-03

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

500 enrolled

Thoracic

Non Squamous Non-small Cell Lung Cancer

NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

480 enrolled

Thoracic

Squamous Non-small Cell Lung Cancer

NCT07109531 2025-08-07

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Phase 3 Not yet recruiting

286 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06970782 2025-05-21

KYLIN-3

Phase 3 Not yet recruiting

278 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06980545 2025-05-20

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

Phase 3 Not yet recruiting

50 enrolled

Gynecologic

Stage III and IV Ovarian Cancer

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

430 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3 Not yet recruiting

355 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase 3 Not yet recruiting

642 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Not yet recruiting

424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Phase 3 Not yet recruiting

368 enrolled

Recurrence

NCT04772287 2021-02-26

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Phase 3 Not yet recruiting

341 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Phase 3 Not yet recruiting

522 enrolled

Breast

Triple Negative Breast Neoplasms